GPPO3: The Impact of Enhanced Recovery Protocol (ERAS) In patients with Peritoneal Surface Malignancies (PSM) Managed with Cytoreductive Surgery (CRS) & Hyperthermic Intraperitoneal Chemotherapy (HIPEC): A Model for Multi-Institutional International Collaboration

Friday, March 24, 2023

10:32 AM – 10:38 AM

Location: Ballroom C

Global Partner Poster(s)

Wael M. Gawad, MD, PhD, FRCS, FSSO

Senior Consultant
National Cancer Institute, Cairo University- Ministry of National Guard Health Affairs-MNGHA-Eastern Province -KSA
Cairo, Egypt

Disclosure(s): No financial relationships to disclose

Disclosure(s):

Wael M. Gawad, MD, PhD, FRCS, FSSO: No financial relationships to disclose

Background: CRS &HIPEC is an increasingly utilized effective approach for PSM which are associated with a dismal prognosis when treated with palliative chemotherapy. Proper patient selection to undergo CRS & HIPEC through a multidisciplinary team and the implementation of ERAS protocols are mandatory for improved outcomes.

Methods: This is a retrospective study comparing the short term surgical and preliminary oncological outcomes in patients undergoing CRS & HIPEC for PSM in the pre (1014-2016) and post (2017-2021) ERAS protocol implementation in 4 tertiary centres in Egypt, USA and KSA.

Results: 130 females & 20 males were enrolled; 75 patients were equally distributed in the Pre & ERAS periods. Disease sites were; ovarian (110), colorectal (18), appendiceal (15) and Gastric Cancer (7). The mean age was 53.1 years, PCI had a mean of 16.8 (